Long-term therapy with estrogen and bazedoxifene alters the microbial composition and activity in the gut, affecting how estrogen is metabolized, a new study in mice found.
According to the study, the enzyme B-glucuronidase (GUS) plays a pivotal role in metabolizing synthetic estrogens in the intestinal tract.
The findings of the study, published in the journal Scientific Reports, suggest that changing the chemistry in the gut could be a way to improve the efficacy and long-term safety of estrogen supplements for postmenopausal women and breast cancer patients.
While the findings need to be replicated in humans, the research offers insight into estrogen-replacement therapy's impact on the expression of microbial genes and may explain why individual patients' responses to hormone therapy can vary, the researchers wrote.
The scientists divided 40 female mice into five treatment groups, which were treated with various estrogens, administered alone or in combination with the estrogen-receptor drug bazedoxifene. The mice were fed a high-fat diet and their ovaries were removed at 10 weeks of age to replicate the estrogen-deficient environment associated with menopause.
After six weeks of treatment, the researchers extracted DNA samples from the mice to examine gene transcription. They also examined the microbiota in the mice's cecums - the pouch at the beginning of the large intestine - and in their fecal samples to assess the microbial diversity and activity in their digestive tracts.
"We observed that both levels of fecal GUS activity and glucuronic acid - a byproduct of estrogen metabolism - decreased after the mice were treated with conjugated estrogens and bazedoxifene," author said. "This supported our hypothesis that estrogen supplementation affects the gut microbiome composition and estrogen metabolism.
"While the overall diversity of microbiota was not changed significantly, we found that the activities of several bacteria taxa were altered by the estrogen therapy," author said. "The levels of several bacteria associated with GUS activity in the gut decreased, including levels of akkermansia," a family of bacteria believed to have anti-inflammatory properties in humans.
Fecal levels of akkermansia were significantly lower in mice treated with the estrogen-bazedoxifene combination compared with their peers in the control group.
However, mice with higher levels of akkermansia in their fecal biome gained more weight, had larger livers and more estrogen metabolites in their systems, the researchers found.
In examining the abundance of common bacterial families in the fecal microbiota, the researchers found higher levels of several microbes, including lactobacillus and streptococcus. Lactobacillus was shown to be associated with GUS activity in previous studies by other researchers while GUS was identified in a subspecies of streptococcus.
The GUS bacteria also interacted with two metabolites of the cancer-inhibiting drug tamoxifen - an important finding because lower serum concentrations of the drug have been linked with poorer outcomes in breast cancer patients, according to the study.
https://news.illinois.edu/view/6367/663288
https://www.nature.com/articles/s41598-018-26506-1
Latest News
Men with gene mutations are…
By newseditor
Posted 17 May
B cell oxidative phosphoryl…
By newseditor
Posted 17 May
Human brain gene therapy us…
By newseditor
Posted 16 May
Small-molecular mimic of a…
By newseditor
Posted 16 May
Centromere structure and ch…
By newseditor
Posted 16 May
Other Top Stories
Interactions between the nervous system and the immune system in ch…
Read more
Human brain compensation in hemispherectomy!
Read more
New players in the fertilization may help to address infertility
Read more
Expert's brain has selective sub networks!
Read more
Inflammation drives tau and amyloid pathologies!
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Obesity-induced blood-brain…
By newseditor
Posted 18 May
CRISPR/Cas9 model of prosta…
By newseditor
Posted 17 May
Modulation of host immunity…
By newseditor
Posted 17 May
Variability in cell divisio…
By newseditor
Posted 17 May
Biallelic BORCS8 variants c…
By newseditor
Posted 17 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar